Method and apparatus for measuring brain synchronization
US-2024408405-A1 · Dec 12, 2024 · US
Light therapy treatment
US8945196B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945196-B2 |
| Application number | US-77113710-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 30, 2010 |
| Priority date | May 1, 2009 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.
First claim
Opening claim text (preview).
The invention claimed is: 1. A light therapy device comprising: a first light source configured to generate light with a first wavelength including 730-770 nm; a second light source configured to generate light with a second wavelength including 950-970 nm; and a processor configured to operate the first and second light sources to inhibit cytochrome c oxidase when applied to organic tissue in response to an ischemia-reperfusion event, wherein the first and second wavelength…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61N5/0613Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945196B2 cover?
- An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying th…
- Who is the assignee on this patent?
- Huttemann Maik, Lee Icksoo, Kamholz John, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61N5/0613. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).